Pko Investment Management Joint Stock CO Akebia Therapeutics, Inc. Transaction History

Pko Investment Management Joint Stock CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Mar 13, 2025	SELL	$1.27 - $2.24 $796,711 - $1.41 Million	-627,332 Closed	0 $0
Q4 2023 Mar 13, 2025	SELL	$0.8 - $1.28 $438,700 - $701,921	-548,376 Closed	0 $0
Q4 2021 Mar 13, 2025	SELL	$2.26 - $3.34 $1.41 Million - $2.08 Million	-622,796 Closed	0 $0
Q3 2021 Mar 13, 2025	SELL	$2.35 - $3.88 $10,659 - $17,599	-4,536 Reduced 0.72%	622,796 $1.79 Billion
Q4 2020 Mar 13, 2025	BUY	$2.22 - $3.78 $1.39 Million - $2.37 Million	627,332 New	627,332 $1.76 Billion
Q2 2020 Mar 13, 2025	BUY	$6.67 - $13.58 $533,800 - $1.09 Million	80,030 Added 14.62%	627,332 $8.52 Billion
Q4 2019 Mar 13, 2025	SELL	$3.16 - $6.73 $3,393 - $7,228	-1,074 Reduced 0.2%	547,302 $3.46 Billion
Q3 2019 Mar 13, 2025	BUY	$3.55 - $5.4 $1.95 Million - $2.96 Million	548,376 New	548,376 $2.15 Billion
Q4 2018 Mar 13, 2025	BUY	$5.39 - $9.15 $2.96 Million - $5.02 Million	548,376 New	548,376 $3.03 Billion

157

96.8M

98.6K

320K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $643M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Pko Investment Management Joint Stock CO, based on Form 13F filings with the SEC.

Stay updated on Pko Investment Management Joint Stock CO with notifications on news.